Thyroid Bioassay for Radioiodine Workers

A thyroid bioassay is a direct measurement of radioiodine in a worker's thyroid gland, used to detect an intake of I-131 (or other radioiodines), estimate the amount taken in, and calculate the resulting committed dose. Because the thyroid concentrates iodine so efficiently, even a small intake can deliver a meaningful committed dose to that single organ — which is exactly why direct thyroid measurement, rather than a whole-body estimate, is the right monitoring tool for radioiodine.¹²

Radioiodine is among the most common internal-exposure concerns in medical facilities. I-131 sodium iodide is volatile, it is handled in therapeutic quantities for thyroid cancer and hyperthyroidism, and it is avidly trapped by the thyroid of anyone who inhales or ingests it. A defensible bioassay program ties the regulatory triggers, measurement timing, instrument calibration, and dose calculation into a documented workflow that the radiation safety officer (RSO) can defend at inspection.²⁶

Introduction

The central fact that drives radioiodine monitoring is biological: iodine goes to the thyroid, and it stays there. A fraction of any systemic radioiodine is trapped by the thyroid within hours and retained with a long biological half-life, so the committed dose to the thyroid from an intake is concentrated rather than diffuse. This makes the thyroid both the organ at risk and the ideal place to make a sensitive measurement.²⁸

That biology has a regulatory consequence. The annual limit on intake (ALI) for I-131 is governed not by the stochastic (whole-body) limit but by the non-stochastic limit to the thyroid — which is why the I-131 inhalation ALI is a relatively small 50 µCi (1.85 MBq), and the corresponding derived air concentration (DAC) is 2 × 10⁻⁸ µCi/mL.³ Monitoring is required when a worker is likely to exceed 10% of that ALI in a year, so the practical trigger for action is an intake on the order of just a few microcuries.³⁴

This guide explains when a thyroid bioassay program is required, how measurements are timed and interpreted, how the committed dose is derived, and how to design a program that satisfies NRC and Agreement State expectations. DRPS supports radioiodine bioassay programs through its radiation safety officer and radioactive material license support services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Topic Explanation

What is a bioassay, and why direct measurement for iodine?

Bioassay is the determination of the kind, quantity, and location of radioactive material in the body, either by direct (in vivo) measurement or by analysis of materials excreted from the body (in vitro). For radioiodine, the direct method dominates: a detector placed over the neck counts the gamma rays emitted by radioiodine that has localized in the thyroid. I-131 emits a 364 keV gamma ray that is well suited to detection with a sodium iodide probe, making in vivo thyroid counting both practical and sensitive.¹⁷

In vitro methods — for example urine analysis — are also used for some radionuclides and circumstances, but for the rapid, organ-specific uptake of iodine, the direct thyroid measurement is the primary tool. The concepts, models, and equations that connect a measurement to an intake and a dose are laid out in NRC Regulatory Guide 8.9 and in NCRP and ICRP guidance.¹⁷⁸

Who needs to be in the program

A worker belongs in a radioiodine bioassay program when they handle unsealed radioiodine in a form and quantity that could plausibly produce an intake. In medical facilities this typically includes:

Nuclear medicine technologists and pharmacists who prepare or administer I-131 sodium iodide therapy capsules or solutions.
Staff providing care to radioiodine therapy patients, who can be a source of airborne or surface contamination.
Radiopharmacy and research personnel who perform iodinations or otherwise process volatile radioiodine.

Sealed sources and many chemically bound radioiodine compounds present lower volatility and therefore lower intake risk, but certain compounds release radioiodine when processed. The RSO evaluates each operation against the regulatory triggers rather than assuming a category is exempt.² For the therapy context that generates much of this risk, see our companion article on I-131 thyroid cancer therapy, and for the broader monitoring framework, occupational exposure monitoring.

Key Technical Principles

The regulatory trigger: 10% of the ALI

The monitoring requirement is set by 10 CFR 20.1502, which requires a licensee to monitor occupational intake and assess committed effective dose equivalent for adults likely to receive, in one year, an intake in excess of 10 percent of the applicable ALI.⁴ For I-131 inhalation:

Monitoring trigger = 0.10 \times ALI = 0.10 \times 50 μ Ci = 5 μ Ci

Because the I-131 ALI is governed by the thyroid (non-stochastic) limit, an intake of one ALI corresponds by definition to the limiting committed dose to the thyroid; the 10% monitoring trigger therefore corresponds to a committed thyroid dose equivalent on the order of 5 rem (0.05 Sv).³⁴ The smallness of these numbers is the whole point: radioiodine demands monitoring at intakes that would be negligible for many other radionuclides.

NRC Regulatory Guide 8.20 translates the 10.1502 requirement into operational triggers. A thyroid bioassay program is recommended when a worker handles unsealed radioiodine above specified activity levels — on the order of 1 mCi of I-131 at an open bench or 10 mCi in a fume hood, evaluated as the cumulative activity handled over a 3-month period — and after any suspected intake, spill, or contamination event.²

From a thyroid measurement to an intake

A single thyroid measurement is a snapshot; converting it to an intake requires the radionuclide's biokinetic model. The model predicts the intake retention fraction (IRF) — the fraction of an intake expected to reside in the thyroid at a given time after intake. The intake is then:

I = \frac{A _{m} ( t )}{IRF ( t )}

where $A_{m} (t)$ is the measured thyroid activity at time $t$ after intake. The IRF accounts for both the uptake of iodine into the thyroid and its subsequent radioactive and biological clearance, and it is taken from the current ICRP biokinetic compilation for the specific radionuclide and intake scenario — it is a model value, not a measured constant.¹⁷⁸

The committed dose then follows from the intake and the committed-dose coefficient $e$ :

CEDE = I \times e

where $e$ is the committed effective dose equivalent per unit intake for the radionuclide and pathway, again drawn from ICRP. The committed dose equivalent to the thyroid is computed analogously with the organ-specific coefficient.⁷⁸

Worked example (illustrative). Suppose a thyroid measurement made 24 hours after a suspected inhalation yields $A_{m} = 0.10 μ Ci$ , and the biokinetic model gives an illustrative IRF of 0.20 at 24 hours for inhaled radioiodine. The estimated intake is:

I = \frac{0.10 μ Ci}{0.20} = 0.50 μ Ci

That is 1% of the 50 µCi ALI — well below the 10% monitoring trigger — and corresponds to a small committed dose. The numbers here are illustrative; an actual assessment uses the IRF and dose coefficients appropriate to the documented exposure conditions and the current ICRP models, not generic values.⁷⁸

Timing, decay correction, and detection limits

Element	What it controls	Practical guidance (per RG 8.20 and bioassay practice)
Measurement timing	How well the snapshot represents the intake	Measure about 6–72 hours after exposure; extend toward ~2 weeks only if a timely assay is impossible²
Decay/clearance correction	Back-calculating intake from the measured burden	Apply the biokinetic IRF, which includes physical decay (I-131 half-life ≈ 8.0 days) and biological clearance¹⁷
Calibration geometry	Converting counts to thyroid activity	Calibrate the probe against a neck phantom with a known activity of the same radionuclide in a thyroid-equivalent geometry¹⁷
Minimum detectable activity (MDA)	Whether the program can see an action-level intake	Set MDA low enough to detect a fraction of the activity corresponding to the investigational level¹⁷
Action / investigational levels	When a result triggers follow-up	Set below regulatory limits; exceeding one prompts confirmation and effective-half-life estimation²

The timing window exists because thyroid uptake rises over the first day while clearance proceeds thereafter; measuring within the 6–72 hour window keeps the correction factors modest and the estimate robust. A measurement that exceeds an action level should be repeated to confirm the result and, for a single intake, to allow an estimate of the effective half-life of radioiodine in the thyroid.²

Clinical Impact

Why early detection matters

The practical value of a bioassay program is not the dose calculation after the fact — it is the chance to catch a failing work practice before it produces a larger intake. A detected thyroid burden, even one corresponding to a small committed dose, is evidence that the engineering controls (fume hood, containment), the procedures, or the personal protective practices let radioiodine reach the worker. Acting on that early signal prevents the next, larger event.

Direct dose measurements of therapy staff illustrate why the controls matter. A study of staff radiation exposure during I-131 thyroid cancer therapy reported annual doses for medical physicists, technologists, and nurses on the order of several hundred microsieverts — below the occupational dose limit, but a clear reminder that handling therapeutic radioiodine is not a zero-dose activity and that both external dose and intake pathways must be managed.¹² According to PubMed, that work is reported by Alkhorayef et al. (DOI).

Investigational levels and the ALARA connection

Bioassay action levels are an ALARA tool, not just a compliance gate. By setting investigational levels well below the regulatory limits, a program converts a single positive result into a prompt to investigate, correct, and re-measure — closing the loop before doses approach a limit. This is the same investigational-level philosophy that underpins external-dose programs; see our guides to building an ALARA program and occupational exposure monitoring. Contamination control on surfaces and in the air is the upstream defense; for survey methods that support it, see choosing the right radiation survey meter.

Practical Optimization Tips

1. Define the triggers in writing

Document, by operation, the activity thresholds that place a worker in the bioassay program, referencing 10 CFR 20.1502 and RG 8.20. Make the 3-month cumulative-activity evaluation explicit so it is applied consistently.

2. Establish baseline and routine measurements

Obtain a baseline thyroid measurement before a worker begins radioiodine work, and schedule routine measurements at a frequency matched to the work pattern, with prompt measurements after any suspected intake, spill, or contamination event.

3. Calibrate to a traceable neck phantom

Calibrate the thyroid probe with a neck phantom containing a known, traceable activity of the radionuclide of interest, and document the calibration, background, and MDA for each measurement cycle.

4. Set action levels below limits and act on them

Set investigational and action levels well below regulatory limits, define the response (confirm, investigate, estimate effective half-life, correct the practice), and record the follow-through.

5. Integrate bioassay with the broader program

Tie bioassay results to air sampling, contamination surveys, engineering controls, and training, so a positive result drives a real corrective action rather than a filed form.

Common pitfalls to avoid

Measuring outside the window. A measurement before ~6 hours or long after 72 hours inflates the correction uncertainty.²
Using generic dose factors. IRF and dose coefficients must match the documented intake scenario and current ICRP models.⁷⁸
Uncalibrated or undocumented MDA. A program that cannot prove its detection limit cannot prove a "negative."
Treating any positive as an overexposure. Action levels are investigation triggers, not limits.
Ignoring the 3-month cumulative rule. Triggers apply to cumulative handled activity, not a single procedure.

Regulatory Considerations

A radioiodine bioassay program must be documented and defensible against the NRC or Agreement State rules that govern the medical use of byproduct material, and it must connect the monitoring trigger, the measurement method, the dose calculation, and the recordkeeping into one auditable workflow. The key frameworks are:

10 CFR Part 20 — Standards for Protection Against Radiation. Section 20.1502 sets the 10%-of-ALI monitoring trigger; 20.1204 governs the determination of internal exposure and the combination of internal and external dose; Appendix B provides the ALI and DAC values, including the I-131 inhalation ALI of 50 µCi and DAC of 2 × 10⁻⁸ µCi/mL.³⁴
NRC Regulatory Guide 8.20, Revision 2 — Applications of Bioassay for Radioiodine — the program-design guidance covering when to bioassay, measurement timing (about 6–72 hours), action levels, and follow-up.²
NRC Regulatory Guide 8.9, Revision 1 — Acceptable Concepts, Models, Equations, and Assumptions for a Bioassay Program — the methodology for converting measurements into intakes and committed doses.¹
NCRP Report No. 87 — Use of Bioassay Procedures for Assessment of Internal Radionuclide Deposition — the technical basis for bioassay program design and interpretation.⁷
ICRP Publication 78 (Individual Monitoring for Internal Exposure of Workers) and the current ICRP dose-coefficient compilations — the biokinetic models and committed-dose coefficients.⁸
NRC NUREG-1556, Volume 9 — program-specific guidance for medical-use licenses, including radiation-safety program expectations relevant to radioiodine handling.⁹

Radioactive material such as I-131 is regulated by the NRC under 10 CFR Parts 20 and 35, or by the equivalent Agreement State program. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that administer their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must verify which authority issues its license and apply that authority's monitoring, action-level, and recordkeeping requirements. DRPS supports this through radioactive material license support, RSO program guidance, and radiation safety training. For related program elements, see common radiation safety violations and how to avoid them.

Frequently Asked Questions (FAQs)

What is a thyroid bioassay?

A thyroid bioassay is a direct (in vivo) measurement of radioiodine in a worker's thyroid gland, made by positioning a detector — typically a sodium iodide thyroid uptake probe — over the neck and counting the gamma emissions from radioiodine taken up by the gland. It is used to detect an intake of radioiodine, estimate the amount taken in, and calculate the resulting committed dose. Because the thyroid avidly concentrates iodine, this measurement is sensitive to even small intakes.

When is a thyroid bioassay required for radioiodine workers?

Under 10 CFR 20.1502, a licensee must monitor occupational intake when a worker is likely to receive, in a year, an intake exceeding 10 percent of the applicable annual limit on intake (ALI). NRC Regulatory Guide 8.20 provides the practical triggers: a thyroid bioassay program is recommended when a worker handles unsealed radioiodine above specified activity levels — for example, on the order of 1 millicurie of I-131 at an open bench or 10 millicuries in a fume hood, evaluated over a 3-month period. Programs should also bioassay after any suspected intake or spill.

How soon after a suspected intake should a thyroid measurement be made?

NRC Regulatory Guide 8.20 recommends performing the thyroid measurement between about 6 and 72 hours after the exposure, with the measurement extended up to roughly two weeks only if circumstances prevent a more timely assay. Measuring too early can miss the peak thyroid uptake, while measuring too late requires larger corrections for radioactive and biological clearance. A follow-up measurement is recommended when an initial result exceeds an action level, both to confirm the result and to estimate the effective half-life.

How is the committed dose calculated from a thyroid measurement?

The measured thyroid activity is corrected back to the time of intake using the radionuclide's biokinetic model, which predicts how much of an intake resides in the thyroid at a given time (the intake retention fraction). Dividing the measured activity by that fraction gives the estimated intake. The intake is then multiplied by the committed-dose coefficient for the radionuclide and intake pathway to obtain the committed effective dose equivalent and the committed dose equivalent to the thyroid. The biokinetic model and dose coefficients come from ICRP and the methods in NRC guidance.

Which workers need bioassay — nuclear medicine, therapy, or radiopharmacy staff?

Any worker who handles unsealed radioiodine in a form and quantity that could produce an airborne or ingestion intake may need bioassay. This commonly includes nuclear medicine technologists and pharmacists who prepare or administer I-131 sodium iodide therapy, staff involved in radioiodine therapy patient care, and radiopharmacy or research personnel performing iodinations. Sealed sources and many bound radioiodine compounds present lower volatility risk; the radiation safety officer evaluates each operation against the regulatory triggers.

What equipment is used to measure thyroid burden?

Thyroid bioassay is typically performed with a sodium iodide (NaI) thyroid uptake probe or a gamma counter, calibrated against a neck phantom containing a known activity of the radionuclide of interest in a thyroid-equivalent geometry. The calibration converts measured counts to thyroid activity. The system's minimum detectable activity must be low enough to detect a fraction of the activity that would correspond to the investigational level, and the calibration and background must be documented for each bioassay.

Does a positive bioassay mean an overexposure?

No. A detectable thyroid burden means an intake occurred, not that a dose limit was exceeded. Bioassay programs use investigational or action levels set well below regulatory limits, so that a result above an action level triggers investigation and follow-up rather than indicating an overexposure. Most detected intakes correspond to small committed doses; the value of bioassay is early detection, dose quantification, and the opportunity to correct the work practice before a larger intake occurs.

Key Takeaways

Iodine concentrates in the thyroid, so a small intake can deliver a meaningful organ dose, and direct thyroid measurement is the right monitoring tool.
The trigger is 10% of the ALI. For I-131 inhalation that is 5 µCi (ALI 50 µCi, DAC 2 × 10⁻⁸ µCi/mL), so monitoring begins at very small intakes.
Timing is 6–72 hours. RG 8.20 sets the measurement window that keeps the intake estimate robust.
Measurement → intake → dose. Divide the measured burden by the intake retention fraction, then multiply by the ICRP dose coefficient.
Action levels are below limits. A positive bioassay triggers investigation, not an automatic overexposure finding.
Document everything. Triggers, calibration, MDA, action levels, and follow-up must form an auditable workflow under 10 CFR Part 20 and RG 8.20/8.9.

Conclusion

Radioiodine is a special case in internal dosimetry precisely because its biology is so predictable: it goes to the thyroid and stays there, concentrating dose in a single organ. That predictability is what makes the thyroid bioassay both necessary and powerful — a quick neck measurement, properly timed and calibrated, can detect an intake at activities far below any dose limit and turn it into a quantified committed dose and a corrected work practice.

A strong program is not complicated, but it must be complete: written triggers tied to 10 CFR 20.1502 and RG 8.20, measurements taken in the 6–72 hour window, a probe calibrated to a traceable neck phantom with a documented MDA, dose calculations built on current ICRP models, and action levels that drive real follow-up. Built that way, a bioassay program protects workers, satisfies the regulator, and — most importantly — catches problems while they are still small.

How DRPS Can Help

Diagnostic Radiation Physics Services helps medical and research facilities design and defend radioiodine bioassay programs as part of its radiation safety officer and radioactive material license support services. This includes establishing monitoring triggers, thyroid-probe calibration and MDA documentation, intake and committed-dose calculations consistent with NRC guidance and ICRP models, action-level definitions, and integration with air sampling, contamination surveys, and radiation safety training.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. To build or review your radioiodine bioassay program, contact our team.

Related Resources

References

U.S. Nuclear Regulatory Commission. Regulatory Guide 8.9, Revision 1: Acceptable Concepts, Models, Equations, and Assumptions for a Bioassay Program. nrc.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.20, Revision 2: Applications of Bioassay for Radioiodine. 2014. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20, Appendix B: Annual Limits on Intake (ALIs) and Derived Air Concentrations (DACs) — Iodine-131. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR 20.1502: Conditions requiring individual monitoring of external and internal occupational dose. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR 20.1204: Determination of internal exposure. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
National Council on Radiation Protection and Measurements. NCRP Report No. 87: Use of Bioassay Procedures for Assessment of Internal Radionuclide Deposition. ncrponline.org
International Commission on Radiological Protection. ICRP Publication 78: Individual Monitoring for Internal Exposure of Workers. Ann ICRP. 1997;27(3-4). icrp.org
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. nrc.gov
International Atomic Energy Agency. IAEA Safety Standards GSG-7: Occupational Radiation Protection. 2018. iaea.org
International Commission on Radiological Protection. ICRP Publication 137: Occupational Intakes of Radionuclides: Part 3. Ann ICRP. 2017;46(3-4). icrp.org
Alkhorayef M, Sulieman A, Mohamed-Ahmed M, et al. Staff and ambient radiation dose resulting from therapeutic nuclear medicine procedures. Appl Radiat Isot. 2018;141:270-274. doi:10.1016/j.apradiso.2018.07.014. PubMed